Abstract
We thank Dr Choi and colleagues for their correspondence and intriguing hypothesis. Unfortunately, we do not have the additional data with which to confidently test the hypothesis stated. We do not have robust osteoporosis data in the Raloxifene Use for the Heart (RUTH) study; we did not systematically measure bone mineral density. In addition, few women (<10% before data lock) reported osteoporosis as a secondary condition. Approximately 15% reported postbaseline use of bone-active agents. For reported …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have